AnaptysBio (NASDAQ:ANAB) Shares Down 6.2% - Here's Why

Key Points

• AnaptysBio shares fell 6.2% on Monday, trading as low as $54.87 after closing at $58.00 the prior day, with volume well below average.
• Several analysts have recently adjusted their views: some downgraded the stock, while others raised price targets; overall, the consensus rating remains Moderate Buy with an average target of $81.82.
• The biotech company reported a wider-than-expected loss in its latest quarter, posting EPS of -$1.84 versus estimates of -$0.64, even though revenue came in above analyst forecasts.

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report)'s stock price fell 6.2% during mid-day trading on Monday . The company traded as low as $54.87 and last traded at $54.4120. 130,067 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 753,997 shares. The stock had previously closed at $58.00.

Wall Street Analyst Weigh In

Several research firms have commented on ANAB. Wall Street Zen downgraded shares of AnaptysBio from a "strong-buy" rating to a "hold" rating in a research report on Saturday, May 16th. Weiss Ratings downgraded AnaptysBio from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, May 13th. UBS Group increased their price objective on AnaptysBio from $60.00 to $76.00 and gave the company a "buy" rating in a report on Wednesday, May 13th. Barclays raised their price objective on AnaptysBio from $63.00 to $75.00 and gave the company an "overweight" rating in a research note on Wednesday, May 13th. Finally, HC Wainwright began coverage on AnaptysBio in a report on Wednesday, June 10th. They issued a "buy" rating and a $95.00 target price for the company. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $81.82.

AnaptysBio Price Performance

The stock's fifty day simple moving average is $59.50 and its 200-day simple moving average is $57.35. The company has a market capitalization of $1.61 billion, a P/E ratio of -50.22 and a beta of 0.68.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($1.20). The firm had revenue of $25.56 million during the quarter, compared to analyst estimates of $18.86 million. On average, research analysts predict that AnaptysBio, Inc. will post -1.35 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has approved a stock buyback program on Friday, March 27th that allows the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization allows the biotechnology company to repurchase up to 5,352,316.2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its stock is undervalued.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ANAB. Vanguard Group Inc. boosted its holdings in AnaptysBio by 4.5% in the 4th quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company's stock valued at $74,855,000 after purchasing an additional 67,048 shares during the period. Sofinnova Investments Inc. increased its holdings in shares of AnaptysBio by 13.1% during the 4th quarter. Sofinnova Investments Inc. now owns 287,690 shares of the biotechnology company's stock worth $13,947,000 after purchasing an additional 33,422 shares during the period. 683 Capital Management LLC raised its position in shares of AnaptysBio by 18.5% during the fourth quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company's stock valued at $31,420,000 after buying an additional 101,093 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of AnaptysBio by 56.0% during the fourth quarter. BNP Paribas Financial Markets now owns 164,823 shares of the biotechnology company's stock valued at $7,991,000 after buying an additional 59,160 shares during the last quarter. Finally, Tema Etfs LLC lifted its stake in shares of AnaptysBio by 105.6% in the fourth quarter. Tema Etfs LLC now owns 22,560 shares of the biotechnology company's stock valued at $1,094,000 after buying an additional 11,585 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.